Hepatic arterial infusion chemotherapy and sorafenib for the treatment of advanced hepatocellular carcinoma patients

Abstract

Sorafenib has been established as a standard therapy to prolong survival in patients with advanced hepatocellular carcinoma patients when locoregional therapy is not indicated; however the benefit of hepatic arterial infusion chemotherapy (HAIC) as an alternative option remains controversial. Although further research to optimize the use of HAIC and sorafenib is ongoing, we present an overview of the factors influencing the management of long-term survival following sorafenib or HAIC treatment.